entertainment -WSS

entertainment

author：entertainment 2025-09-06 03:57:41 - browse：2

A DNA helix, with dollar banknotes covering its strands, collapses next to another DNA helix with dollar banknotes strands — coverage from STAT — Adobe

The closely watched gene-editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with another biotech it partnered with to develop a potentially powerful new form of genome editing.

Prime and Myeloid Therapeutics, a startup co-founded by Pulitzer Prize-winning writer and cancer biologist Siddhartha Mukherjee, have filed competing arbitration claims over a deal they signed in March 2022.

Prime, spun out of the lab of Broad Institute biochemist David Liu, was built on technology for making small insertions, deletions, and single-letter changes in DNA. In theory, prime editing allows researchers to tackle the vast majority of disease-causing mutations, and the first treatments are already being readied for clinical trials. But it’s a poor fit in cases where hundreds or even thousands of different mutations in a long gene cause the same diseases, such as cystic fibrosis or Duchenne muscular dystrophy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Radiology is caught between AI's potential and concern for patients

focus

WSS

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Spinal cord stimulation reduces pain in amputees, study finds

Pregnancy discrimination could be enabled by AI

Congenital heart disease patients face new threat of heart failure

STAT Readout: Friday, Oct. 20 biotech updates

FDA clears Verve to begin U.S. study of gene

knowledge

entertainment

focus

Bright Health sells Medicare Advantage business to Molina

Is there really a nursing shortage in the U.S.?

Peter Hotez and the public health issue of online harassment

UnitedHealth, Optum discontinue NaviHealth name

Cancer drug shortages should be causing more outrage

Smaller biotechs seek to piggyback on weight loss drug boom

In Memoriam: Notable people who died in 2023

Why a market frenzy over new weight loss drugs defies logic

Cancer drug shortages should be causing more outrage

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

entertainment

Roivant's CEO is a star, but biotech's black hole persists

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Roche to buy Carmot Therapeutics, developer of obesity drugs

AI models in health care face new federal disclosure requirements

Teach medical students about patients with intellectual disabilities

Why sickle cell disease is getting the first CRISPR treatment

knowledge

knowledge

focus

focus